Advertisement

Topics

Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT

2018-05-30 21:24:11 | BioPortfolio

Published on BioPortfolio: 2018-05-30T21:24:11-0400

Clinical Trials [385 Associated Clinical Trials listed on BioPortfolio]

Prostatic Artery Embolization for Obstructive Uropathy Due to Locally Advanced Prostate Cancer

The aim of this study is to investigate the safety and efficacy of prostatic artery embolization of patients with recurrent symptoms secondary to locally advanced prostatic cancer includin...

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in me...

Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer

The purpose of this study is to test the use of the Prostatic Urethral Lift (PUL), Urolift®, in prostate cancer (Pca) participants seeking or undergoing radiotherapy for relief of urinary...

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at me...

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.

PubMed Articles [645 Associated PubMed Articles listed on BioPortfolio]

Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to AMPHICRINE carcinoma.

Prostatic neuroendocrine manifestations encompass a heterogeneous spectrum of morphological entities. In the era of evidence-based and precision-led treatment, distinction of biologically relevant cli...

18F-NaF PET/CT in Prostatic Calculi.

Primary prostatic calculi commonly present asymptomatically in men over the age of 50 years. Individual calculi form when the secretory tube is blocked by inflammation, prostatic secretions, or corpor...

Recanalization of prostatic artery chronic total occlusion prior to prostatic artery embolization.

Urinary obstruction secondary to benign prostatic hyperplasia is a late manifestation of the disease, and a poor prognostic sign for responding to conservative therapies. Prostatic artery embolization...

Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.

Prostatic artery embolization (PAE) has been introduced into clinical practice for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS) despite a lack of ...

The UroLift® system for treatment of the benign prostatic syndrome (BPS).

Minimally-invasive treatment options for patients with LUTS due to benign prostatic obstruction (BPO) become more and more important because they provide equal long-term efficacy compared with the ref...

Medical and Biotech [MESH] Definitions

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Tumors or cancer of the PROSTATE.

A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.

A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

More From BioPortfolio on "Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial